Remove 2015 Remove Designs Remove Public Use
article thumbnail

Intellectual Property Tools for Protecting Fashion Goods

LexBlog IP

Below are three possible situations in which you can use intellectual property tools with respect to a product’s nature, originality, consumer driven features, and potential for growth. In the event that infringement occurs, a designer must show that the infringer copied the designers copyrighted work. [5] ” [8]. .”

article thumbnail

Lawfare in the orphan drug space

43(B)log

Neurelis received orphan drug designation from the FDA for its Valtoco for management of ARS in 2015. It then received fast strack designation, which allowed it priority review, and filed an NDA for Valtoco in 2018; this was pending at the time of the operative complaint.

Design 56
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Intellectual Property Tools for Protecting Fashion Goods

Above the Fold

Below are three possible situations in which you can use intellectual property tools with respect to a product’s nature, originality, consumer driven features, and potential for growth. In the event that infringement occurs, a designer must show that the infringer copied the designers copyrighted work. [5]

article thumbnail

I was already like this before you got here: prior use as an exception to patent infringement

Garrigues Blog

In an earlier blog, we discussed “prior public use” as grounds for opposing the grant of European patents (see here ). In addition, a third party’s use of an invention before its registration by another is also relevant to assess patent infringement. Real intention to use.

article thumbnail

Biosimilars 2020 Year in Review

Fish & Richardson Trademark & Copyright Thoughts

The biosimilar pathway was designed to increase competition for biologics and reduce healthcare costs. For the first time since FDA licensed the first biosimilar, Sandoz’s Zarxio ® (filgrastim-sndz), in 2015, the United States saw a decrease in annual biosimilar approvals in 2020. 2015; resubmitted Feb. 2015; resubmitted Dec.